tirzepatide reactive hypoglycemia and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism How to control reactive hypoglycemia

Preliminary evidence also suggests that tirzepatide may confer cardiovascular benefits by improving lipid metabolism (e.g., lowering LDL cholesterol) and reducing inflammation (e.g., lowering C-reactive protein)

However, long-term safety data, especially regarding cardiovascular safety, still need further accumulation

They received tirzepatide 5 mg, 10 mg, 15 mg, and dulaglutide 0.75 mg, with the primary endpoint being the mean change in HbA1c from baseline to week 52

Chepurny et al., 2019

The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database